NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
9 trialsNCT06091865 2026-02-05
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT01324596 2016-04-15
REMoDL-B
University Hospital Southampton NHS Foundation Trust
Phase 3 Completed
NCT00003815 2013-09-17
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00002576 2013-08-07
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005867 2013-06-26
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed